Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Doxorubicin 4Sunitinib 3Radiosurgery 3Everolimus 3pembrolizumab 2exemestane 2Tamoxifen 2Specimen Handling 2Octreotide 2Magnetic Resonance Spectroscopy 2Fulvestrant 2Filgrastim 2Biopsy 2Bevacizumab 23-Iodobenzylguanidine 2tislelizumab 1surufatinib 1romidepsin 1regorafenib 1penpulimab 1pasireotide 1mercaptoundecahydrododecaborate 1lutetium Lu 177 dotatate 1lanreotide 1ganitumab 1folfirinox 1fludarabine phosphate 1epothilone B 1entrectinib 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × BAY 1895344 × Endocrine × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡